Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3058420 | 1.00 | BACE1 (0.40) | BACE1BACE2ALPIPKMPTGS1 | |
| SCHEMBL3050414 | 0.92 | BACE1 (0.38) | BACE1BACE2ALPIPKMPTGS1 | |
| SCHEMBL3060236 | 0.92 | BACE1 (0.38) | BACE1BACE2ALPIPKMPTGS1 | |
| SCHEMBL3044603 | 0.90 | TDP1 (0.45) | POLBMEN1KMT2AMAPTTDP1 | |
| SCHEMBL3047220 | 0.90 | TDP1 (0.45) | POLBMEN1KMT2AMAPTTDP1 | |
| SCHEMBL3058401 | 0.88 | HTR1A (0.44) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3045269 | 0.88 | HTR1A (0.44) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3059936 | 0.88 | HTR1A (0.44) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3052727 | 0.86 | NR1I2 (0.39) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3057173 | 0.86 | NR1I2 (0.39) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | BACE1 765/4885BACE2 671/4885ALPI 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.